Key Points TransMedics delivered revenue and net income growth of 48% and 111% in its first-quarter earnings. The company continues to see streamlining efficiencies from its nascent logistical network. Solidly profitable and with a promising growth story, TransMedics remains one of my favorite investments. 10 stocks we like better than TransMedics Group › Shares of next-generation transplant technology platform TransMedics(NASDAQ: TMDX) were up 21% as of noon ET on Friday, according to data provided by S&P Global Market Intelligence. TransMedics reported first-quarter results that saw revenue balloon 48% and the company's net income margin rise from 13% a year ago to 18% today. On top of these results blowing away analysts' expectations, management raised its 2025 sales guidance from 23% at the midpoint to 30%, sparking an optimistic reaction from the market. TransMedics' in-house logistics are paying early dividends TransMedics' Organ Care System (OCS) and National OCS Platform (NOP) have moved the organ transplant industry into a new era. As opposed to the less-effective, traditional ice storage previously used in transplants, the company's OCS keeps livers, hearts, and lungs perfused with blood and functioning while in transit to a donee. While this upgrade alone allows for longer travel time for donated organs (and higher success rates), TransMedics took things to the next level when it started to buy planes for its logistics services in 2023.Image source: Getty Images. Immediately put to use in 49% of NOP flight missions in Q1 of 2024, the company's planes now cover 78% of these flights in Q1 2025. This streamlining logistical network helped TransMedics' net income spike 111% from last year and makes the company a true end-to-end solution for organ transplants. However, just because TransMedics has seemingly reached new levels of profitability, don't think its growth days are over. Transplanting 3,715 organs in 2024 -- and I'd guess somewhere slightly above 1,000 in Q1 -- the company believes it can grow to 10,000 transplants by 2028. With its next-gen lung and heart systems -- the company's smaller segments -- set to enter clinical trials later this year, TransMedics should have plenty of growth ahead. Should you invest $1,000 in TransMedics Group right now? Before you buy stock in TransMedics Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Story Continues Consider whenNetflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation,you’d have $617,181!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation,you’d have $719,371!* Now, it’s worth notingStock Advisor’s total average return is909% — a market-crushing outperformance compared to163%for the S&P 500. Don’t miss out on the latest top 10 list, available when you joinStock Advisor. See the 10 stocks » *Stock Advisor returns as of May 5, 2025 Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy. Why TransMedics Stock Is Skyrocketing Today was originally published by The Motley Fool View Comments
Why TransMedics Stock Is Skyrocketing Today
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...